Orexo AB (publ.), announces it has filed a patent infringement action in the United States District Court for the District of New Jersey, against Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma Global, Inc., and Sun Pharmaceutical Industries, Inc.
Sun Pharmaceutical Industries Ltd.and Ranbaxy Laboratories Ltd have announced that they have entered into definitive agreements pursuant to which Sun...
Sun Pharma announced the acquisition of 14 established prescription brands from Novartis AG and Novartis Pharma AG in Japan. According...
Sun Pharmaceutical Industries Ltd. announced that Sun Pharma has received approval for CEQUA (cyclosporine ophthalmic solution) 0.09%, from the FDA....
Sun Pharmaceutical announced that its arm Sun Pharma Canada Inc. has received Health Canada approval for Abscorba LD (isotretinoin capsules) to treat acne
Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from FDA for its Abbreviated New...
Sun Pharmaceutical Industries Ltd and its subsidiaries or associate companies announced its plans to acquire a branded oncology product, Odomzo...
Cassiopea SpA and Sun Pharmaceutical Industries Ltd have .announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%), The agreements are effective as of August 31, 2021.
Sunovion has announced positive results from the Phase III clinical trial program for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist...
Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of $8.00 per share of common stock in cash, or $576 million in equity value.